Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study

被引：0
|
作者：
Redman, B. G.
Hudes, G. R.
Kim, S. T.
Chen, I.
Motzer, R. J.
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[2] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[3] Pfizer Global Res & Dev, La Jolla, CA USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16014
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [42] Side effects of sunitinib malate (SM) treatment for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Carteni, G. G.
    Montano, M.
    Perrotta, E.
    Otero, M.
    Guida, T.
    Ragone, G.
    Aurilio, G.
    Maiorino, L.
    Stavolo, C.
    Panza, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study
    Atkins, Michael B.
    Ravaud, Alain
    Gravis, Gwenaelle
    Drosik, Kazimierz
    Demkow, Tomasz
    Tomczak, Piotr
    Kracht, Karolyn
    Puhlmann, Markus
    Weinreich, David Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] SUNITINIB IN PATIENTS (PTS) WITH OR WITHOUT PRIOR NEPHRECTOMY IN AN EXPANDED-ACCESS STUDY OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Szczylik, C.
    Porta, C.
    Bracarda, S.
    Hawkins, R.
    Bjarnason, G. A.
    Oudard, S.
    Kee, S. H.
    Carteni, G.
    Hariharan, S.
    Gore, M.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [45] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    [J]. BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [46] Phase I trial of sunitinib (S) and temsirolimus (T) in metastatic renal cell carcinoma (mRCC)
    Campbell, Matthew T.
    Millikan, Randall E.
    Altinmakas, Emre
    Xiao, Lianchun
    Tannir, Nizar M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [47] SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) WITH BRAIN METASTASES (METS): DATA FROM AN EXPANDED-ACCESS STUDY
    Bracarda, S.
    Hariharan, S.
    Szczylik, C.
    Porta, C.
    Hawkins, R.
    Bjarnason, G. A.
    Oudard, S.
    Lee, S. H.
    Carteni, G.
    Gore, M.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 182 - 182
  • [48] PHASE II MULTICENTRIC STUDY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) WITH A POOR PROGNOSIS REFRACTORY TO IMMUNOTHERAPY
    Longo, N.
    Di Lorenzo, G.
    Fusco, F.
    Verze, P.
    Barba, C.
    Arcaniolo, D.
    Mirone, V
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 183 - 183
  • [49] Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A GION trial.
    Porta, Camillo
    Ferrari, Vittorio D.
    Zucali, Paolo Andrea
    Fornarini, Giuseppe
    Bernardo, Antonio
    Falconeri, Andrea
    Ferrari, Alessandra
    Santarossa, Sandra
    Pappagallo, Giovanni L.
    Bearz, Alessandra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Updated results from a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Rini, Brian I.
    Mcdermott, David F.
    Lewis, Lionel D.
    Voss, Martin H.
    Sharma, Padmanee
    Pal, Sumanta K.
    Razak, Albiruni
    Kollmannsberger, Christian
    Heng, Daniel Y. C.
    Spratlin, Jennifer
    Mchenry, M. Brent
    Gagnier, Paul
    Amin, Asim
    [J]. BJU INTERNATIONAL, 2016, 118 : 20 - 21
12345